ArticleMolecular and cellular biochemistry2026
CYP2U1: a cardiac metabolic switch alleviating obesity cardiomyopathy via lipid metabolic reprogramming.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cytochrome P450 2U1 (CYP2U1) modulates lipid metabolism, yet its role in obesity-induced cardiomyopathy remains unknown. Here, we demonstrate that cardiac-specific overexpression of CYP2U1 safeguards against high-fat diet (HFD)-induced myocardial dysfunction. Mice received tail-vein injection of adeno-associated virus serotype 9 (AAV9) carrying CYP2U1 under the cardiac troponin T promoter (AAV9-cTnT-CYP2U1) and were maintained on a 16-week HFD. Cardiac-specific CYP2U1 overexpression was associated with better preservation of systolic function and with reduced myocardial hypertrophy, interstitial fibrosis, and cardiac inflammation. By combining transcriptomics, untargeted metabolomics, and oxylipidomics, we identified two protective mechanisms. Transcriptomic analysis indicated that CYP2U1 attenuated multiple inflammatory cascades, including nuclear factor-κB (NF-κB) p65 phosphorylation and nuclear translocation, with a corresponding reduction in interleukin-6 (IL-6) transcription; CCAAT/enhancer-binding protein β (C/EBPβ) may contribute to this regulation. Metabolomic analysis suggested that CYP2U1 remodels polyunsaturated fatty acid metabolism, consistent with a "metabolic switch" that shifts the balance away from pro-inflammatory arachidonic acid-derived hydroxyeicosatetraenoic acids (HETEs) toward the docosahexaenoic acid (DHA) pathway, with increased levels of the protective lipid mediators 19,20-epoxydocosapentaenoic acid (19,20-EDP) and protectin DX (PDX). In vitro, CYP2U1 overexpression in palmitic acid-challenged H9C2 cells reproduced these anti-inflammatory and metabolic features. CYP2U1 therefore limits obesity-driven cardiac inflammation by coupling suppression of the NF-κB/C/EBPβ-IL-6 axis with a shift in lipid mediators toward DHA-derived specialized pro-resolving mediators. Whether targeted activation of CYP2U1 can be translated into a therapeutic strategy for obesity-associated cardiomyopathy warrants further investigation.
Indexed as
Identifiers
42867812What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.